Tratamento neoadjuvante no câncer de mama (2010)
- Authors:
- Autor USP: HEGG, ROBERTO - FM
- Unidade: FM
- Subjects: NEOPLASIAS MAMÁRIAS (MORTALIDADE); FATORES SOCIOECONÔMICOS; QUIMIOTERAPIA ADJUVANTE
- Language: Português
- Imprenta:
- Source:
- Título: Prática Hospitalar
- ISSN: 1677-0447
- Volume/Número/Paginação/Ano: v. 12, n. 71, p. 25-30, set/out., 2010
-
ABNT
HEGG, Roberto et al. Tratamento neoadjuvante no câncer de mama. Prática Hospitalar, v. 12, n. 71, p. 25-30, 2010Tradução . . Acesso em: 24 jan. 2026. -
APA
Hegg, R., Mattar, A., Rigoni, V., & Ávila, M. (2010). Tratamento neoadjuvante no câncer de mama. Prática Hospitalar, 12( 71), 25-30. -
NLM
Hegg R, Mattar A, Rigoni V, Ávila M. Tratamento neoadjuvante no câncer de mama. Prática Hospitalar. 2010 ; 12( 71): 25-30.[citado 2026 jan. 24 ] -
Vancouver
Hegg R, Mattar A, Rigoni V, Ávila M. Tratamento neoadjuvante no câncer de mama. Prática Hospitalar. 2010 ; 12( 71): 25-30.[citado 2026 jan. 24 ] - Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial
- Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
- Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial
- Bolero-4: A Phase 2, Open-Label, multicenter, single-arm trial investigating the efficacy and safety of first-line everolimus (EVE) in combination with letrozole (LET) in postmenopausal patients (PTS) with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) metastatic or locally advanced unresectable breast cancer (BC)
- Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer
- Hormonioterapia neoadjuvante no câncer de mama
- Superexpressao do oncogene her-2/neu em carcinomas de mama: analise clinica e imunohistoquimica
- Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
- Terapia estrogenica e cancer de mama
- Efficacy and safety of Bevacizumab-Containing therapy in newly diagnosed ovarian cancer ROSiA Single-Arm Phase 3B Study
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
